Current in silico methods for multi-target drug discovery in early anticancer research: the rise of the perturbation-theory machine learning approach

References

• 1. Global Burden of Disease Cancer C, Kocarnik JM, Compton K et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. JAMA Oncol. 8(3), 420–444 (2022).
  MedlineGoogle Scholar
• 2. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J. Health Econ. 47, 20–33 (2016).
  MedlineGoogle Scholar
• 3. Dominguez-Valentin M, Nakken S, Tubeuf H et al. Results of multigene panel testing in familial cancer cases without genetic cause demonstrated by single gene testing. Sci. Rep. 9(1), 18555 (2019).
  Medline CASGoogle Scholar
• 4. Ramsay RR, Popovic-Nikolic MR, Nikolic K, Uliassi E, Bolognesi ML. A perspective on multi-target drug discovery and design for complex diseases. Clin. Transl. Med. 7(1), 3 (2018).
  MedlineGoogle Scholar
• 5. Schaduangrat N, Lampa S, Simeon S, Gleeson MP, Spjuth O, Nantasenamat C. Towards reproducible computational drug discovery. J. Cheminformatics 12(1), 9 (2020).
  MedlineGoogle Scholar
• 6. Raghavendra NM, Pingili D, Kadasi S, Mettu A, Prasad S. Dual or multi-targeting inhibitors: the next generation anticancer agents. Eur. J. Med. Chem. 143, 1277–1300 (2018).
  Medline CASGoogle Scholar
• 7. Simeon S, Ghislat G, Ballester P. Characterizing the relationship between the chemical structures of drugs and their activities on primary cultures of pediatric solid tumors. Curr. Med. Chem. 28(38), 7830–7839 (2021).
  Medline CASGoogle Scholar
• 8. Halder AK, Moura AS, Cordeiro MNDS. Moving average-based multitasking in silico classification modeling: where do we stand and what is next? Int. J. Mol. Sci. 23(9), 4937 (2022).
  MedlineGoogle Scholar
• 9. Speck-Planche A, Cordeiro MNDS. Speeding up early drug discovery in antiviral research: a fragment-based in silico approach for the design of virtual anti-hepatitis C leads. ACS Comb. Sci. 19(8), 501–512 (2017).
  Medline CASGoogle Scholar
• 10. Munteanu CR, Gutierrez-Asorey P, Blanes-Rodriguez M et al. Prediction of anti-glioblastoma drug-decorated nanoparticle delivery systems using molecular descriptors and machine learning. Int. J. Mol. Sci. 22(21), 11519 (2021).
  Medline CASGoogle Scholar
• 11. Santana R, Zuluaga R, Ganan P et al. PTML model for selection of nanoparticles, anticancer drugs, and vitamins in the design of drug-vitamin nanoparticle release systems for cancer cotherapy. Mol. Pharm. 17(7), 2612–2627 (2020).
  Medline CASGoogle Scholar
• 12. Bediaga H, Arrasate S, Gonzalez-Diaz H. PTML combinatorial model of ChEMBL compounds assays for multiple types of cancer. ACS Comb. Sci. 20(11), 621–632 (2018).
  Medline CASGoogle Scholar
• 13. Kleandrova VV, Speck-Planche A. PTML modeling for pancreatic cancer research: in silico design of simultaneous multi-protein and multi-cell inhibitors. Biomedicines 10(2), 491 (2022).
  Medline CASGoogle Scholar
• 14. Kleandrova VV, Scotti MT, Scotti L, Speck-Planche A. Multi-target drug discovery via PTML modeling: applications to the design of virtual dual inhibitors of CDK4 and HER2. Curr. Top. Med. Chem. 21(7), 661–675 (2021).
  Medline CASGoogle Scholar
• 15. Kleandrova VV, Scotti MT, Scotti L, Nayarisseri A, Speck-Planche A. Cell-based multi-target QSAR model for design of virtual versatile inhibitors of liver cancer cell lines. SAR QSAR Environ. Res. 31(11), 815–836 (2020).
  Medline CASGoogle Scholar
• 16. Patinote C, Karroum NB, Moarbess G et al. Agonist and antagonist ligands of toll-like receptors 7 and 8: ingenious tools for therapeutic purposes. Eur. J. Med. Chem. 193, 112238 (2020).
  Medline CASGoogle Scholar
• 17. Speck-Planche A, Kleandrova VV, Scotti MT. In silico drug repurposing for anti-inflammatory therapy: virtual search for dual inhibitors of caspase-1 and TNF-alpha. Biomolecules 11(12), 1832 (2021).
  Medline CASGoogle Scholar
• 18. Zhu G, Chen X. Aptamer-based targeted therapy. Adv. Drug Deliv. Rev. 134, 65–78 (2018).
  Medline CASGoogle Scholar
• 19. Garofalo M, Leva GD, Croce CM. MicroRNAs as anti-cancer therapy. Curr. Pharm. Des. 20(33), 5328–5335 (2014).
  Medline CASGoogle Scholar
• 20. Speck-Planche A, Cordeiro MNDS. De novo computational design of compounds virtually displaying potent antibacterial activity and desirable in vitro ADMET profiles. Med. Chem. Res. 26(10), 2345–2356 (2017).
  CASGoogle Scholar